This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Akorn: the Pharmaceutical Stock You Can’t Afford to Ignore

NEW YORK (TheStreet) -- A San Diego-based biopharmaceutical company is gaining international attention for an experimental Ebola treatment that just saved two lives.

Mapp Biopharmaceutical is that company. Although it might sound like it employs hundreds, it actually employs only nine.

It shipped three vials containing an experimental Ebola drug to two American aid workers in Liberia. It was a last-ditch effort to save their lives while their families were making funeral arrangements back in the U.S. Fortunately, those funerals were canceled.

I know what you may be thinking: What’s the ticker symbol for Mapp Biopharmaceutical? Well, unfortunately Mapp Biopharmaceuticals is not a publicly traded company; it is privately held.

But let’s hear it for the biotech and pharma stocks. These past two to three years have brought some amazing advances in the field of drug discovery and therapeutic medicine.

Drug stocks continue to be one of the best areas in the market. One name that I continue to own in my Aggressive Growth Account is Akorn (AKRX - Get Report). And this company is actually public, though you may not know much about it.

Akorn, based in Lake Forest, Ill., is a niche generic pharmaceutical company that develops and markets pharmaceuticals in the areas of ophthalmology, hospital drugs and injectables. Stocks like this have been big winners in the past six months. Akorn in particular ranks as a Gunderson Trophy Winner, making it rare and mighty. I have only 10 Trophy Winner stocks in my 3,850 stock universe.

Let’s examine what makes Akorn a Trophy Winner at Gunderson Capital Management:

Data from Best Stocks Now App

Akorn has a market cap of $3.6 billion. Back in 2010, Akorn traded at $1 per share. Today the stock is at $37 per share. While Akorn may not be a mighty oak quite yet, it is well on its way.

Data from Best Stocks Now App

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AKRX $46.75 0.67%
FB $94.58 -2.50%
GOOG $629.86 -0.33%
TSLA $263.11 -0.27%
YHOO $37.55 -0.32%

Markets

Chart of I:DJI
DOW 17,746.95 -4.44 -0.02%
S&P 500 2,106.06 -2.51 -0.12%
NASDAQ 5,120.8420 +9.1090 0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs